NCT06057051 Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma
| NCT ID | NCT06057051 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Glaukos Corporation |
| Condition | Glaucoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 245 participants |
| Start Date | 2023-09-01 |
| Primary Completion | 2025-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 245 participants in total. It began in 2023-09-01 with a primary completion date of 2025-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment
Eligibility Criteria
Inclusion Criteria: * Diagnosis of primary open-angle glaucoma * Phakic or pseudophakic * Age 35 years or older Exclusion Criteria: * Traumatic, uveitic, neovascular, angle-closure glaucoma or * glaucoma associated with vascular disorders * Active corneal inflammation or edema * Retinal disorders not associated with glaucoma
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06057051 clinical trial?
This trial is open to participants of all sexes, aged 35 Years or older, studying Glaucoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06057051 currently recruiting?
Yes, NCT06057051 is actively recruiting participants. Contact the research team at dparizadeh@glaukos.com for enrollment information.
Where is the NCT06057051 trial being conducted?
This trial is being conducted at Cincinnati, United States.
Who is sponsoring the NCT06057051 clinical trial?
NCT06057051 is sponsored by Glaukos Corporation. The trial plans to enroll 245 participants.